iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $19.00 by Analysts at Wells Fargo & Company

iTeos Therapeutics (NASDAQ:ITOS - Free Report) had its price target reduced by Wells Fargo & Company from $31.00 to $19.00 in a research note released on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages have also commented on ITOS. Wedbush reiterated an "outperform" rating and set a $25.00 price target on shares of iTeos Therapeutics in a research note on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of iTeos Therapeutics in a report on Friday, December 13th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS traded down $0.04 during midday trading on Thursday, hitting $7.22. 440,766 shares of the company's stock were exchanged, compared to its average volume of 444,466. The firm's fifty day simple moving average is $8.59 and its 200-day simple moving average is $12.71. The company has a market cap of $263.78 million, a PE ratio of -2.29 and a beta of 1.37. iTeos Therapeutics has a twelve month low of $7.12 and a twelve month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.13. Equities analysts anticipate that iTeos Therapeutics will post -3.46 EPS for the current fiscal year.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall acquired 5,000 shares of iTeos Therapeutics stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 12.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Candriam S.C.A. purchased a new position in iTeos Therapeutics in the second quarter worth $7,558,000. State Street Corp grew its stake in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company's stock worth $12,000,000 after purchasing an additional 211,452 shares during the period. Clearline Capital LP purchased a new position in shares of iTeos Therapeutics in the 2nd quarter valued at about $2,328,000. Algert Global LLC lifted its stake in shares of iTeos Therapeutics by 92.0% in the third quarter. Algert Global LLC now owns 256,139 shares of the company's stock valued at $2,615,000 after purchasing an additional 122,730 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company's stock valued at $13,481,000 after purchasing an additional 117,159 shares during the period. 97.16% of the stock is owned by hedge funds and other institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.